EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The most common adverse reactions for Dupixent overall are injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes and eosinophilia. In addition, the adverse ...

TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent ...

The most common adverse reactions for Dupixent overall are injection site reactions, conjunctivitis, conjunctivitis allergic, arthralgia, oral herpes and eosinophilia. In addition, the adverse ...

Regeneron announced Friday that the company won Food and Drug Administration approval for Dupixent in chronic obstructive ...

(NASDAQ: REGN) and Sanofi (NASDAQ:SNY) have reported positive outcomes from a Phase 3 trial of Dupixent (dupilumab) in patients with chronic spontaneous urticaria (CSU) who have not responded ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi have announced that the European Commission has granted approval for Dupixent (dupilumab) to be utilized in the treatment of ...